Form 8-K - Current report:
SEC Accession No. 0000950170-24-123252
Filing Date
2024-11-07
Accepted
2024-11-07 16:03:10
Documents
13
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alxo-20241105.htm   iXBRL 8-K 53134
2 EX-99.1 alxo-ex99_1.htm EX-99.1 149545
3 GRAPHIC img62044099_0.jpg GRAPHIC 148612
  Complete submission text file 0000950170-24-123252.txt   527016

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alxo-20241105.xsd EX-101.SCH 26051
15 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20241105_htm.xml XML 4537
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 241435436
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)